Detalhe da pesquisa
1.
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Ann Rheum Dis
; 83(2): 199-213, 2024 Jan 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37793792
2.
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
Ann Rheum Dis
; 82(4): 515-526, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36649967
3.
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Arthritis Rheumatol
; 74(12): 1943-1958, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35829672